Pharming Group N.V.: Angioedemas, Hereditary trials
The registry lists 11 Angioedemas, Hereditary studies with Pharming Group N.V. as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 2 7Phase 3 4No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 InhibitorCompletedNCT02247739Phase 2Results posted
- Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) PatientsCompletedNCT01359969Phase 2Results posted
- Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksCompletedNCT01188564Phase 3Results posted
- A Study of the Safety and Immunogenicity of Repeated rhC1INH AdministrationCompletedNCT00851409Phase 2Results posted
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262301Phase 3Results posted
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00225147Phase 2/3Results posted
- Patient Registry to Evaluate the Real-world Safety of Ruconest®CompletedNCT03697187
- C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) AttacksCompletedNCT01397864
- Recombinant Human C1 Inhibitor for the Treatment of Early Antibody-Mediated Rejection in Renal TransplantationWithdrawnNCT01035593Phase 2
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00262288Phase 2/3
- Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary AngioedemaCompletedNCT00261053Phase 2